Investor Presentaiton
R&D investor presentation
In the STEP 1 trial, people treated with semaglutide had a
superior weight loss of up to 16.9%
The pivotal STEP 1 trial showed greater than
Data from STEP 1
% change in
body weight
0
-2
-4
-6
-8
-10
-12
-14
-16
-18
-20
04
8 12 16 20
16% weight loss
•
Average age 46
Placebo: -2.4%
•
74.1% women
•
Average BMI - 37.9 kg/m²
Semaglutide: -16.9%
36
44
52
60
68
28
Time since initiation (weeks)
Change in body weight in % depicts observed means since time of randomisation; trial product estimand.
BMI: body mass index; SF-36: Short Form (36) Health Survey; IWQOL-lite-CT: Impact of Weight on Quality of Life-Lite questionnaire
Improvements in lipid profiles as well as C-
reactive protein
Semaglutide improved health-related
quality of life as measured by SF-36 and
IWQOL-lite-CT
novo nordisk
33
33View entire presentation